Core Viewpoint - Dongyang Sunshine Pharmaceutical has made strategic adjustments to its sales structure by establishing a dedicated team for liver disease, aiming to accelerate the commercialization of innovative drugs for hepatitis C amidst fierce competition in the influenza drug market [3]. Group 1 - The company has recently formed a specialized team focused on liver diseases to enhance its market presence [3]. - This move is part of the company's strategy to seek new growth points in response to intense competition in the influenza drug sector [3].

Group 1 - The company, Dongyang Sunshine Pharmaceutical, has made a sales structure adjustment in August, establishing a dedicated team for liver disease to accelerate the commercialization of innovative drugs for hepatitis C and other conditions [2] - Dongyang Sunshine Pharmaceutical is known as the "king of flu drugs" and is seeking new growth points for performance amid fierce competition in the flu drug market [2]

Core Viewpoint - The company is accelerating the commercialization of innovative drugs such as those for hepatitis C, following a sales structure adjustment made in August [1] Group 1 - The company has established a dedicated team for liver disease to enhance its market presence in this area [1] - The company, known as the "king of flu drugs," is seeking new growth points due to intense competition in the flu medication market [1]

Core Viewpoint - Insurance companies are actively increasing their stakes in listed companies, with a notable rise in the number of equity investments made by insurance funds in 2023, indicating a strong willingness to invest in the stock market [1][2]. Group 1: Recent Activities - On August 13, China Pacific Life Insurance Co., Ltd. announced its stake increase in Guangdong Dongyangguang Pharmaceutical Co., Ltd. through the acquisition of H-shares [1]. - As of August 13, the total number of equity stakes taken by insurance funds in listed companies reached 27 this year, significantly higher than the 20 instances recorded in the previous year [2]. Group 2: Investment Strategies - The stake increase in Dongyangguang Pharmaceutical was triggered by a share swap during the privatization of its Hong Kong-listed subsidiary, indicating a strategic move to consolidate holdings [2]. - After the stake increase, China Pacific Life directly held approximately 6.06 million H-shares of Dongyangguang, representing 5.38% of the company's H-share capital [2]. Group 3: Market Conditions and Regulations - Regulatory changes have encouraged insurance companies to increase their equity investments, with a focus on long-term assessment mechanisms and adjustments to solvency rules that lower risk factors for stock investments [3]. - The overall equity investment by insurance companies accounted for approximately 20.6% of total investment as of the first quarter of this year, reflecting a gradual increase in equity asset allocation [4]. Group 4: Future Outlook - Industry experts believe there is still significant room for increasing equity asset allocation, as many insurance companies have not yet reached their investment limits based on solvency ratios [5]. - The current market environment and accounting standards suggest that insurance funds are likely to continue increasing their equity investments in the near future [5].

Core Viewpoint - Insurance companies are actively increasing their stakes in listed companies, with a notable rise in the number of equity investments this year, indicating a strong willingness to enhance equity asset allocation [3][4][6]. Group 1: Recent Activities - On August 13, China Pacific Life Insurance Co., Ltd. announced that it and its affiliates have increased their stake in Guangdong Dongyangguang Pharmaceutical Co., Ltd. by acquiring H-shares [3]. - As of August 13, the total number of equity stakes taken by insurance funds this year has reached 27, significantly higher than the 20 instances recorded for the entire previous year [5][6]. Group 2: Investment Trends - The majority of the 27 instances of stake increases this year were driven by active buying, with only 2 instances being triggered by passive factors, reflecting a strong intent among insurance funds to increase their holdings in listed companies [5][6]. - The main methods of stake acquisition include competitive trading and secondary market purchases, primarily funded by self-owned capital and insurance liability reserves [5]. Group 3: Regulatory Environment - Recent regulatory changes have established actionable assessment standards for the proportion and stability of insurance funds entering the A-share market, promoting a long-term assessment mechanism [6]. - Adjustments to solvency rules by the National Financial Regulatory Administration have reduced the risk factors for stock investments, encouraging insurance funds to increase their market participation [6]. Group 4: Equity Asset Allocation - The proportion of equity assets held by insurance companies is gradually increasing, with the overall equity investment accounting for approximately 20.6% of total fund utilization as of the first quarter of this year [7]. - Regulatory guidelines specify that the equity asset balance must not exceed certain percentages of total assets based on the solvency ratio, allowing for significant room for future increases in equity allocations [7][8]. Group 5: Company-Specific Insights - China Ping An Life Insurance Co., Ltd. reported a solvency ratio of 227.92% as of the first quarter, allowing for an equity investment limit of 30%, with its equity assets accounting for 23.26% of total assets [8]. - China Post Life Insurance Co., Ltd. had a solvency ratio of 194.59% at the end of the second quarter, with equity assets making up 17.08% of total assets, indicating substantial potential for future equity allocation [8].

Core Viewpoint - The insurance sector is actively increasing its equity asset allocation, with significant potential for future growth in this area [1][4]. Group 1: Insurance Companies' Activities - China Pacific Life Insurance Co., Ltd. announced its recent acquisition of shares in Guangdong Dongyangguang Pharmaceutical Co., Ltd., holding approximately 605.86 million shares, which represents 5.38% of the latter's H-share capital [2]. - As of August 13, 2023, the total number of equity stakes acquired by insurance capital reached 27 this year, significantly higher than the 20 instances recorded in the previous year [2]. - The majority of these acquisitions were driven by proactive buying, indicating a strong willingness among insurance companies to increase their holdings in listed companies [2]. Group 2: Regulatory Environment - Recent regulatory changes have established actionable assessment standards for the proportion and stability of large state-owned insurance companies' investments in A-shares, promoting a long-term assessment mechanism [3]. - Adjustments to solvency rules have reduced the risk factors associated with stock investments, encouraging insurance capital to increase market participation [3]. Group 3: Equity Asset Allocation - The proportion of equity assets in insurance companies is gradually increasing, with equity investments accounting for approximately 20.6% of total investment assets as of the first quarter of this year [4]. - Regulatory guidelines dictate that the equity asset balance must not exceed certain thresholds based on the solvency ratio, allowing for a structured approach to equity investment [4]. Group 4: Future Outlook - Analysts believe that there is still considerable room for insurance companies to increase their equity asset allocation, as many companies are currently below their investment limits [5]. - The current capital market environment and accounting standards suggest that insurance capital is likely to continue expanding its equity asset holdings in the future [5].

Summary of Key Points from the Conference Call Industry Overview - The conference call primarily discusses the **express delivery and logistics industry** in China, with a focus on the impact of recent regulatory changes and market dynamics on various companies within the sector [1][2][3]. Core Insights and Arguments - **Price Increases in Express Delivery**: The express delivery industry is witnessing initial success in reversing the trend of price undercutting, with multiple regions experiencing price hikes due to severe losses among franchisees and regulatory pressure for market stability. This price increase is expected to be more sustainable compared to the isolated price hikes in Yiwu in 2021, benefiting from the upcoming peak demand season [1][6][7]. - **Recommendations for E-commerce Delivery Companies**: Companies with strong service quality and cash flow, such as **ZTO Express** and **YTO Express**, are recommended. Additionally, **J&T Express** is highlighted for its competitive position in Southeast Asia, while **SF Express** is noted for its stable high-end service business [1][8]. - **Cross-border E-commerce Logistics**: The volume of air cargo to the U.S. has recovered to 70% of pre-tariff levels, which is better than expected. Eastern Airlines Logistics is performing well with high load factors, and despite a decrease in freight rates, the situation remains favorable. A dividend yield of 4.7% suggests a potential investment opportunity if tariffs improve or volumes increase [1][9]. - **Airline Sector Performance**: The airline sector is experiencing weak ticket prices but good passenger volumes. The fundamentals are well-reflected, and factors like oil prices and exchange rates may provide benefits. **Huaxia Airlines** is recommended due to its leading position in regional aviation and improved subsidy standards, which enhance profit certainty [1][23]. - **Rail Freight Outlook**: **Tielong Logistics** is favored due to its special container business benefiting from equipment upgrades and strong synergy with upstream steel companies. The potential for profit elasticity exists due to the ongoing reversal of price undercutting [1][21][22]. Additional Important Insights - **July Performance of the Transportation Sector**: The overall transportation sector saw a decline of 0.2%, underperforming the CSI 800 index by 4.2 percentage points. Sub-sectors like airports, shipping, and logistics performed relatively well, with increases of 4.3%, 2.4%, and 1.2%, respectively [2]. - **Market Sentiment and Future Recommendations**: The call suggests a continued focus on companies benefiting from the reversal of price undercutting in express delivery, core assets in aviation and express sectors, and stocks in cross-border logistics with potential catalysts from mid-year earnings reports [3]. - **Logistics Sector Performance**: The logistics sector saw a 1.2% increase, with road freight leading at 5.9%. Cross-border logistics rose by 3.3%, while express delivery only increased by 0.6%, reflecting market skepticism about the sustainability of the recovery [5]. - **Future Trends in Container Shipping**: Container shipping rates have shown a downward trend in July, with expectations of continued pressure in August due to high base effects and tariff impacts. The overall volume is expected to stabilize, but rates may continue to decline [12]. - **Air Cargo Market Dynamics**: The air cargo market is expected to maintain low supply levels, particularly for long-haul routes, while domestic airlines are enhancing their logistics capabilities. Positive outcomes from U.S.-China negotiations could serve as a catalyst for growth [30]. - **Investment Recommendations for Airport Stocks**: The airport sector is advised to focus on companies with stable earnings and high dividend yields, especially in light of recent performance and potential geopolitical events that could impact market conditions [15][31]. This summary encapsulates the key points discussed in the conference call, providing insights into the current state and future outlook of the express delivery and logistics industry.

香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本聯合公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 本聯合公告僅供參考，並不構成收購、購買或認購本公司證券之邀請或要約，亦 非在任何司法管轄區招攬任何投票或批准。 本聯合公告不會在構成違反任何司法管轄區相關法律的情況下於或向有關司法管 轄區發佈、刊發或派發。 廣東東陽光藥業股份有限公司 SUNSHINE LAKE PHARMA CO ., LTD . (2) 就零碎股安排委聘代理人 要約人的財務顧問 （ 一間於中華人民共和國註冊成立的有限公司 ） 宜昌東陽光長江藥業股份有限公司 YICHANG HEC CHANGJIANG PHARMACEUTICAL CO ., LTD . （ 在中華人民共和國註冊成立之股份有限公司 ） （股份代號：6887） （股份代號：1558） 聯合公告 以吸收合併宜昌東陽光長江藥業股份有限公司之方式 由廣東東陽光藥業股份有限公司 對宜昌東陽光長江藥業股 ...

【财华社讯】东阳光长江药业(01558.HK)公布，联交所已经批准撤销H股在联交所的上市地位，于2025 年8月5日下午四时正起生效。 本文源自：财华网 ...

东阳光长江药业（01558）发布公告，宣布香港交易所已批准撤销公司H股在联交所的上市地位，撤销将于2025年8月5日下午4时生效。公告中指出，H股股东应在联交所网站查看由要约人发布 根据公告，换股比率为1股H股可换取0.263614股要约人H股。换股股东所获得的要约人H股数量将为整数，若计算后未能达到整数，则会按小数点后尾数排序，依次给予额外股份，直至实际换股 ...